New Data Highlight Adult Pneumococcal Serotypes with Greater Antibiotic Resistance and Disease Burden Covered by Merck’s Vaccine

Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. Adults

RAHWAY, N.J.--(BUSINESS WIRE)--Oct 21, 2025-

New Data Highlight Adult Pneumococcal Serotypes with Greater Antibiotic Resistance and Disease Burden Covered by Merck’s Vaccine

A systematic review presented at IDWeek 2025 found that pneumococcal serotypes unique to Merck’s 21-valent conjugate vaccine, Capvaxive, are more prevalent among US adults and show higher rates of antibiotic resistance compared to those unique to PCV20.